Related Experiment Video
Updated: Jul 11, 2025
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma
Jiawen Yang1, James T Lim2, Paul Victor3
1University of Arizona Cancer Center, Tucson, Arizona, USA.
Abstract:
Merkel Cell Carcinoma (MCC) is an aggressive neuroendocrine cutaneous malignancy arising from either ultraviolet-induced mutagenesis or Merkel cell polyomavirus (MCPyV) integration. Despite extensive research, our understanding of the molecular mechanisms driving the transition from normal cells to MCC remains limited. To address this knowledge gap, we assessed the impact of inducible MCPyV T antigens on normal human fibroblasts by performing RNA sequencing. Our data uncovered changes in expression and regulation of Wnt signaling pathway members. Building on this observation, we bioinformatically evaluated various Wnt pathway perturbagens for their ability to reverse the MCC gene expression signature and identified pyrvinium pamoate, an FDA-approved anthelminthic drug known for its anti-tumor activity in other cancers. Leveraging transcriptomic, network, and molecular analyses, we found that pyrvinium targets multiple MCC vulnerabilities. Pyrvinium not only reverses the neuroendocrine features of MCC by modulating canonical and non-canonical Wnt signaling but also inhibits cancer cell growth by activating p53-mediated apoptosis, disrupting mitochondrial function, and inducing endoplasmic reticulum stress. Finally, we demonstrated that pyrvinium reduces tumor growth in an MCC mouse xenograft model. These findings offer a new understanding of the role of Wnt signaling in MCC and highlight the utility of pyrvinium as a potential treatment for MCC.
Insights
Pyrvinium pamoate, an antihelminthic drug, shows promise in treating Merkel Cell Carcinoma (MCC). It reverses cancer-promoting Wnt signaling and induces cancer cell death, reducing tumor growth in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Virology
Background:
- Merkel Cell Carcinoma (MCC) is an aggressive skin cancer with limited treatment options.
- The molecular drivers of MCC, particularly the role of Merkel cell polyomavirus (MCPyV) T antigens, are not fully understood.
- Wnt signaling pathway dysregulation is implicated in various cancers, but its specific role in MCC requires further investigation.
Purpose of the Study:
- To investigate the molecular mechanisms underlying MCC development.
- To identify therapeutic strategies targeting MCC.
- To evaluate the potential of pyrvinium pamoate as an MCC treatment.
Main Methods:
- RNA sequencing of human fibroblasts expressing MCPyV T antigens.
- Bioinformatic analysis of Wnt pathway perturbagens.
- Transcriptomic, network, and molecular analyses of pyrvinium pamoate effects.
- In vivo testing using an MCC mouse xenograft model.
Main Results:
- MCPyV T antigens alter Wnt signaling pathway gene expression in fibroblasts.
- Pyrvinium pamoate was identified as a potential Wnt pathway modulator for MCC.
- Pyrvinium pamoate reversed MCC neuroendocrine features by modulating Wnt signaling.
- Pyrvinium pamoate induced cancer cell apoptosis via p53 activation, mitochondrial dysfunction, and ER stress.
- Pyrvinium pamoate significantly reduced tumor growth in an MCC mouse model.
Conclusions:
- Wnt signaling plays a crucial role in MCC pathogenesis.
- Pyrvinium pamoate demonstrates multi-targeted anti-cancer activity against MCC.
- Pyrvinium pamoate represents a promising therapeutic candidate for Merkel Cell Carcinoma treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...